Is Amedisys, Inc. overvalued or undervalued?

As of 8 May 2025, Amedisys, Inc. has moved from a fair to an expensive valuation grade. The company is currently considered overvalued. Key ratios include a P/E ratio of 20.53, an EV to EBITDA of 15.59, and a PEG ratio of 0.31, which suggests that despite a low growth expectation, the stock price remains high relative to earnings growth potential.
In comparison to its peers, Amedisys stands out with a significantly higher P/E ratio than Guardant Health, which has a P/E of -14.92, and Azenta, which has a P/E of -73.61, indicating that Amedisys is priced at a premium despite the overall riskiness of the sector. Additionally, the company's recent stock performance has outpaced the S&P 500 over the past month, returning 4.72% compared to the index's 3.83%, but the long-term performance remains concerning with a 5-year decline of 50.66%.